{"id":3099,"date":"2018-08-23T16:24:16","date_gmt":"2018-08-23T10:54:16","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3099"},"modified":"2021-07-24T12:57:02","modified_gmt":"2021-07-24T07:27:02","slug":"the-business-cocktail-37","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-37","title":{"rendered":"AZ dragout Entasis; Sierra remunerates Gilead; Principia raises; Harbour BioMed and Kelun pen deal"},"content":{"rendered":"<p><strong>AstraZeneca dragout Entasis files to fund antibiotic phase 3 for USD 86 Million IPO <\/strong><\/p>\n<p>Massachusetts-based <strong>Entasis Therapeutics<\/strong> has spun out to raise up to <strong>USD 86 Million<\/strong> through an IPO. The AstraZeneca spinout is attempting to fund a phase 3 trial of a drug to overcome bacterial resistance to beta-lactams. In 2015, Entasis spun out of AstraZeneca with an antibiotic drug discovery platform. Since then, Entasis has requested <strong>USD 86 Million<\/strong> from Clarus Lifesciences, Novo Holdings and Frazier Life Sciences, that enables it to lead candidate to the cusp of phase 3.<\/p>\n<p><strong>Sierra remunerates Gilead late-stage cancer drug with just USD 3 Million upfront<\/strong><\/p>\n<p><strong>Sierra Oncology<\/strong> reimburses <strong>Gilead<\/strong> for an unwanted late-stage cancer drug,\u00a0momelotinib,myelofibrosis with a tiny upfront of just <strong>USD 3 Million<\/strong>, with <strong>USD195 Million<\/strong> on the table in bio dollars if all goes according to the plan. Although a minor bite for Gilead, this matters a lot to Sierra.<\/p>\n<p><strong>Principia Biopharma raises up for USD 86Million IPO<\/strong><\/p>\n<p>South San Francisco-based <strong>Principia Biopharma<\/strong> has lined up <strong>USD 86.3 Million<\/strong> in its IPO to carry its lead asset into phase 3. The company&#8217;s<strong> Bruton\u2019s Tyrosine Kinase (BTK)<\/strong> inhibitor is presently in phase 2 trials for the autoimmune skin disease, pemphigus and is also being developed for a bleeding disorder i.e. immune thrombocytopenic purpura (ITP). The biopharma\u00a0authorized to Sanofi, a different BTK inhibitor, PRN2246. This is for multiple sclerosis and opens the use for other neurological disorders. \u00a0Principia taken up USD 40 Million upfront and will notch up to <strong>USD 765 million<\/strong> in milestone payments.<\/p>\n<p><strong>Harbour BioMed and Kelun pen USD 350 Million PD-L1 agreement <\/strong><\/p>\n<p>Shanghai-based <strong>Harbour BioMed<\/strong>\u00a0permitted\u00a0a midphase <a href=\"https:\/\/www.delveinsight.com\/report-store\/anti-cd274-pd-l1-antibody-pipeline-insight\"><strong>PD-L1<\/strong><\/a> antibody from <strong>Kelun Biotech<\/strong> for development and commercialization outside of Greater China. Kelun will earn up to <strong>USD 350 Million<\/strong>.\u00a0Harbour and Kelun has the second deal in the PD-L1 partnership. Under their first collaboration, the companies agreed to co-discover, co-develop and commercialize antibodies against innovative targets that is based on Harbour\u2019s fully human antibody discovery platforms.<\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>\u00a0<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca dragout Entasis files to fund antibiotic phase 3 for USD 86 Million IPO Massachusetts-based Entasis Therapeutics has spun out to raise up to USD 86 Million through an IPO. The AstraZeneca spinout is attempting to fund a phase 3 trial of a drug to overcome bacterial resistance to beta-lactams. In 2015, Entasis spun out [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2290,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1720,638,96,17664,137,1709,17663,716,794,1393,1714,1718,1717,1715,1711,427,1716,17661,1712,1710,1719],"industry":[17225],"therapeutic_areas":[17227,17231,17228],"class_list":["post-3099","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-antibiotic","tag-antibody","tag-astrazeneca","tag-brutonas-tyrosine-kinase","tag-cancer","tag-entasis","tag-entasis-therapeutics","tag-funding","tag-gilead","tag-gilead-sciences","tag-harbour-biomed","tag-inhibitor","tag-jak1-2","tag-kelun-biotech","tag-momelotinib","tag-oncology","tag-pd-l1","tag-principia","tag-principia-biopharma","tag-sierra","tag-skin-disease","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-infectious-diseases","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>AZ dragout Entasis; Sierra remunerates Gilead; Principia raises<\/title>\n<meta name=\"description\" content=\"Massachusetts-based Entasis Therapeutics has spun out to raise up to USD 86 Million through an IPO. The AstraZeneca spinout is attempting....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-37\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AZ dragout Entasis; Sierra remunerates Gilead; Principia raises\" \/>\n<meta property=\"og:description\" content=\"Massachusetts-based Entasis Therapeutics has spun out to raise up to USD 86 Million through an IPO. The AstraZeneca spinout is attempting....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-37\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-08-23T10:54:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021353\/pharma-licensing.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"620\" \/>\n\t<meta property=\"og:image:height\" content=\"414\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AZ dragout Entasis; Sierra remunerates Gilead; Principia raises","description":"Massachusetts-based Entasis Therapeutics has spun out to raise up to USD 86 Million through an IPO. The AstraZeneca spinout is attempting....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-37","og_locale":"en_US","og_type":"article","og_title":"AZ dragout Entasis; Sierra remunerates Gilead; Principia raises","og_description":"Massachusetts-based Entasis Therapeutics has spun out to raise up to USD 86 Million through an IPO. The AstraZeneca spinout is attempting....","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-37","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-08-23T10:54:16+00:00","article_modified_time":"2021-07-24T07:27:02+00:00","og_image":[{"width":620,"height":414,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021353\/pharma-licensing.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-37","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-37","name":"AZ dragout Entasis; Sierra remunerates Gilead; Principia raises","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-37#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-37#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021353\/pharma-licensing.jpg","datePublished":"2018-08-23T10:54:16+00:00","dateModified":"2021-07-24T07:27:02+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Massachusetts-based Entasis Therapeutics has spun out to raise up to USD 86 Million through an IPO. The AstraZeneca spinout is attempting....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-37"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-37#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021353\/pharma-licensing.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021353\/pharma-licensing.jpg","width":620,"height":414,"caption":"Entasis"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021353\/pharma-licensing-300x200.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">antibiotic<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Antibody<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AstraZeneca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bruton\u00e2\u0080\u0099s Tyrosine Kinase<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Entasis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Entasis Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Funding<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gilead<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">gilead sciences<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Harbour BioMed<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Inhibitor<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">JAK1\/2<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Kelun Biotech<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">momelotinib<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Oncology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">PD-L1<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Principia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Principia Biopharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sierra<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">skin disease<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">antibiotic<\/span>","<span class=\"advgb-post-tax-term\">Antibody<\/span>","<span class=\"advgb-post-tax-term\">AstraZeneca<\/span>","<span class=\"advgb-post-tax-term\">Bruton\u00e2\u0080\u0099s Tyrosine Kinase<\/span>","<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">Entasis<\/span>","<span class=\"advgb-post-tax-term\">Entasis Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Funding<\/span>","<span class=\"advgb-post-tax-term\">Gilead<\/span>","<span class=\"advgb-post-tax-term\">gilead sciences<\/span>","<span class=\"advgb-post-tax-term\">Harbour BioMed<\/span>","<span class=\"advgb-post-tax-term\">Inhibitor<\/span>","<span class=\"advgb-post-tax-term\">JAK1\/2<\/span>","<span class=\"advgb-post-tax-term\">Kelun Biotech<\/span>","<span class=\"advgb-post-tax-term\">momelotinib<\/span>","<span class=\"advgb-post-tax-term\">Oncology<\/span>","<span class=\"advgb-post-tax-term\">PD-L1<\/span>","<span class=\"advgb-post-tax-term\">Principia<\/span>","<span class=\"advgb-post-tax-term\">Principia Biopharma<\/span>","<span class=\"advgb-post-tax-term\">Sierra<\/span>","<span class=\"advgb-post-tax-term\">skin disease<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Aug 23, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Aug 23, 2018 4:24 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3099","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3099"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3099\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2290"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3099"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3099"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3099"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3099"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3099"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}